- Home
- IQI vs FENC Comparison
IQI vs FENC Comparison
Compare IQI & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$10.12
Company Overview
Basic Information| Metric | IQI | FENC |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 460.1M | 366.8M |
| IPO Year | 1994 | 2010 |
Fundamental Metrics
Financial Performance| Metric | IQI | FENC |
|---|---|---|
| Price | $8.85 | $10.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | ★ 305.2K | 109.3K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $62.55 |
| Revenue Next Year | N/A | $42.10 |
| P/E Ratio | ★ N/A | $172.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.47 | $5.65 |
| 52 Week High | $10.42 | $13.25 |
Technical Indicators
Market Signals| Indicator | IQI | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 41.23 | 43.15 |
| Support Level | $8.47 | $9.87 |
| Resistance Level | $9.95 | $10.66 |
| Average True Range (ATR) | 0.16 | 0.50 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 43.21 | 27.27 |
Price Performance
Historical Comparison IQI
FENC
About IQI Invesco Quality Municipal Income Trust
Invesco Quality Municipal Income Trust is a diversified, closed-end management investment company. Its investment objective is to provide current income which is exempt from federal income tax.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.